Once again, Denver, Colorado is at the heart of the U.S. drug debate. Instead of marijuana, though, this time they are debating the decriminalization of psilocybin mushrooms. Initiative 301 is on the ballot, and if passed, psilocybin mushrooms would become Denver’s lowest law enforcement priority. This wouldn’t exactly legalize shrooms though.
The FDA just approved a new antidepressant, the first of its kind. Unlike other antidepressants, this one is a nasal spray. Esketamine, under the brand name Spravato, is developed by Johnson & Johnson and has been in testing for the past 2 years. The drug has seen remarkable success. This success is interesting because the drug is closely tied to the club drug “Special K.” Related to MDMA, Special K is known as Ecstasy. This marks the first major breakthrough in the treatment of depression since the 1980s.